NF 023 | CAS# 99777-90-9 | P2X1 purinoceptor antagonist

MedKoo Cat#: 414360 | Name: NF 023

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NF 023 is a potent, selective P2X1 purinoceptor antagonist.

Chemical Structure

NF 023

CAS#99777-90-9 (free acid)

Theoretical Analysis

MedKoo Cat#: 414360

Name: NF 023

CAS#: 99777-90-9 (free acid)

Chemical Formula: C35H26N4O21S6

Exact Mass: 1029.9414

Molecular Weight: 1030.96

Elemental Analysis: C, 40.78; H, 2.54; N, 5.43; O, 32.59; S, 18.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

99777-90-9 (free acid) 104869-31-0 (sodium)

Synonym

NF 023; NF023; NF-023

IUPAC/Chemical Name

1,3,5-Naphthalenetrisulfonic acid, 8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino))bis-

InChi Key

JMONOAYAUIIKMS-UHFFFAOYSA-N

InChi Code

InChI=1S/C35H26N4O21S6/c40-33(38-25-7-9-27(63(49,50)51)23-13-21(61(43,44)45)15-29(31(23)25)65(55,56)57)17-3-1-5-19(11-17)36-35(42)37-20-6-2-4-18(12-20)34(41)39-26-8-10-28(64(52,53)54)24-14-22(62(46,47)48)16-30(32(24)26)66(58,59)60/h1-16H,(H,38,40)(H,39,41)(H2,36,37,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)

SMILES Code

O=C(NC1=CC(C(NC2=CC=C(S(=O)(O)=O)C3=CC(S(=O)(O)=O)=CC(S(=O)(O)=O)=C23)=O)=CC=C1)NC4=CC(C(NC5=CC=C(S(=O)(O)=O)C6=CC(S(=O)(O)=O)=CC(S(=O)(O)=O)=C56)=O)=CC=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,030.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sorrentino L, Cossu F, Milani M, Malkoc B, Huang WC, Tsay SC, Ru Hwu J, Mastrangelo E. Structure-Activity Relationship of NF023 Derivatives Binding to XIAP-BIR1. ChemistryOpen. 2019 Apr 12;8(4):476-482. doi: 10.1002/open.201900059. PMID: 31011505; PMCID: PMC6460348. 2: Cossu F, Milani M, Grassi S, Malvezzi F, Corti A, Bolognesi M, Mastrangelo E. NF023 binding to XIAP-BIR1: searching drugs for regulation of the NF-κB pathway. Proteins. 2015 Apr;83(4):612-20. doi: 10.1002/prot.24766. Epub 2015 Feb 5. PMID: 25619915. 3: Minic Z, O'Leary DS, Reynolds CA. Purinergic receptor antagonism: A viable strategy for the management of autonomic dysreflexia? Auton Neurosci. 2021 Jan;230:102741. doi: 10.1016/j.autneu.2020.102741. Epub 2020 Nov 16. PMID: 33220530. 4: Cossu F, Sorrentino L, Fagnani E, Zaffaroni M, Milani M, Giorgino T, Mastrangelo E. Computational and Experimental Characterization of NF023, A Candidate Anticancer Compound Inhibiting cIAP2/TRAF2 Assembly. J Chem Inf Model. 2020 Oct 26;60(10):5036-5044. doi: 10.1021/acs.jcim.0c00518. Epub 2020 Sep 4. PMID: 32820924. 5: Silva-Ramos M, Silva I, Faria M, Ferreirinha F, Correia-de-Sá P. Activation of Prejunctional P2x2/3 Heterotrimers by ATP Enhances the Cholinergic Tone in Obstructed Human Urinary Bladders. J Pharmacol Exp Ther. 2020 Jan;372(1):63-72. doi: 10.1124/jpet.119.261610. Epub 2019 Oct 21. PMID: 31636173. 6: DiGiacomo V, de Opakua AI, Papakonstantinou MP, Nguyen LT, Merino N, Blanco- Canosa JB, Blanco FJ, Garcia-Marcos M. The Gαi-GIV binding interface is a druggable protein-protein interaction. Sci Rep. 2017 Aug 17;7(1):8575. doi: 10.1038/s41598-017-08829-7. PMID: 28819150; PMCID: PMC5561080. 7: Liang S, Connell GJ. Identification of specific inhibitors for a trypanosomatid RNA editing reaction. RNA. 2010 Dec;16(12):2435-41. doi: 10.1261/rna.2347310. Epub 2010 Oct 12. PMID: 20940340; PMCID: PMC2995404. 8: Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez JJ, Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN. Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. Nucleic Acids Res. 2012 Sep 1;40(17):8607-21. doi: 10.1093/nar/gks623. Epub 2012 Jun 27. PMID: 22740655; PMCID: PMC3458564. 9: Gil V, Gallego D, Grasa L, Martín MT, Jiménez M. Purinergic and nitrergic neuromuscular transmission mediates spontaneous neuronal activity in the rat colon. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G158-69. doi: 10.1152/ajpgi.00448.2009. Epub 2010 Apr 15. PMID: 20395536. 10: Lambrecht G. Design and pharmacology of selective P2-purinoceptor antagonists. J Auton Pharmacol. 1996 Dec;16(6):341-4. doi: 10.1111/j.1474-8673.1996.tb00049.x. PMID: 9131412.